PCVX Annual Cash & Cash Equivalents
$397.45 M
-$437.21 M-52.38%
31 December 2023
Summary:
As of January 22, 2025, PCVX annual cash & cash equivalents is $397.45 million, with the most recent change of -$437.21 million (-52.38%) on December 31, 2023. During the last 3 years, it has risen by +$11.25 million (+2.91%). PCVX annual cash & cash equivalents is now -52.38% below its all-time high of $834.66 million, reached on December 31, 2022.PCVX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCVX Quarterly Cash And Cash Equivalents
$1.05 B
+$531.52 M+102.48%
30 September 2024
Summary:
As of January 22, 2025, PCVX quarterly cash and cash equivalents is $1.05 billion, with the most recent change of +$531.52 million (+102.48%) on September 30, 2024. Over the past year, it has increased by +$505.06 million (+92.65%). PCVX quarterly cash and cash equivalents is now at all-time high.PCVX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCVX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.4% | +92.7% |
| 3 y3 years | +2.9% | +837.3% |
| 5 y5 years | +501.4% | - |
PCVX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.4% | +476.1% | at high | +1422.3% |
| 5 y | 5-year | -52.4% | +573.9% | at high | +1680.7% |
| alltime | all time | -52.4% | +573.9% | at high | +1680.7% |
Vaxcyte Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.05 B(+102.5%) |
| June 2024 | - | $518.67 M(-15.2%) |
| Mar 2024 | - | $611.51 M(+53.9%) |
| Dec 2023 | $397.45 M(-52.4%) | $397.45 M(-27.1%) |
| Sept 2023 | - | $545.13 M(+2.7%) |
| June 2023 | - | $531.03 M(+39.6%) |
| Mar 2023 | - | $380.45 M(-54.4%) |
| Dec 2022 | $834.66 M | $834.66 M(+199.8%) |
| Sept 2022 | - | $278.40 M(+16.9%) |
| June 2022 | - | $238.17 M(+18.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $201.74 M(+192.4%) |
| Dec 2021 | $68.98 M(-82.1%) | $68.98 M(-38.4%) |
| Sept 2021 | - | $112.04 M(-25.8%) |
| June 2021 | - | $151.00 M(-24.1%) |
| Mar 2021 | - | $198.94 M(-48.5%) |
| Dec 2020 | $386.20 M(+554.8%) | $386.20 M(-2.7%) |
| Sept 2020 | - | $397.05 M(-3.2%) |
| June 2020 | - | $410.05 M(+164.9%) |
| Mar 2020 | - | $154.79 M(+162.5%) |
| Dec 2019 | $58.98 M(-10.8%) | $58.98 M |
| Dec 2018 | $66.09 M | - |
FAQ
- What is Vaxcyte annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Vaxcyte?
- What is Vaxcyte annual cash & cash equivalents year-on-year change?
- What is Vaxcyte quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Vaxcyte?
- What is Vaxcyte quarterly cash and cash equivalents year-on-year change?
What is Vaxcyte annual cash & cash equivalents?
The current annual cash & cash equivalents of PCVX is $397.45 M
What is the all time high annual cash & cash equivalents for Vaxcyte?
Vaxcyte all-time high annual cash & cash equivalents is $834.66 M
What is Vaxcyte annual cash & cash equivalents year-on-year change?
Over the past year, PCVX annual cash & cash equivalents has changed by -$437.21 M (-52.38%)
What is Vaxcyte quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PCVX is $1.05 B
What is the all time high quarterly cash and cash equivalents for Vaxcyte?
Vaxcyte all-time high quarterly cash and cash equivalents is $1.05 B
What is Vaxcyte quarterly cash and cash equivalents year-on-year change?
Over the past year, PCVX quarterly cash and cash equivalents has changed by +$505.06 M (+92.65%)